



# Combat Drugs Limited

Regd. Off: 4<sup>th</sup> Floor, Plot No. 94,  
Sagar Society, Road No.2,  
Banjara Hills, Hyderabad – 500 034  
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,  
Road No. 14, Gayatri Nagar,  
Bouduppall, Hyd - 500039, T.S  
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100  
Url: www.combatdrugs.in  
Email: info@combatdrugs.in  
GST: 36AAACC8372L1ZB

12<sup>th</sup> August, 2019

To,  
The General Manager  
Department of Corporate Services - CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai 400 001

Dear Sir,

## **Sub: Outcome of Board Meeting – Quarterly Results**

Dear Sir,

Further to our letter dated 1<sup>st</sup> August, 2019, we would like to inform that the Board of Directors of the Company at its meeting held today ie; 12<sup>th</sup> August, 2019 at 04.00 P.M and concluded at 06.00 P.M., have approved the Un-Audited Financial Results for the quarter ended 30<sup>th</sup> June, 2019.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-Audited Standalone Financial Results for the quarter ended 30<sup>th</sup> June, 2019.
2. Un-Audited Consolidated Financial Results for the Quarter ended 30<sup>th</sup> June, 2019.
3. Auditors' Report on the Standalone and Consolidated Financial Results for the Quarter.

Please Note that the opinion given by the Statutory Auditor in the Enclosed Audit Report is unmodified opinion.

We kindly request you to take the same on record.

Thanking You,  
Yours Sincerely,  
For **COMBAT DRUGS LIMITED**

Kumar Raghavan  
**COMPANY SECRETARY &  
COMPLIANCE OFFICER**



**COMBAT DRUGS LIMITED**

Regd Office : 4th Floor,Plot No.94,Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

**Consolidated Unaudited Financial Results For the Quarter ended 30 June 2019**

*All amounts in ₹ Lakhs, unless otherwise stated*

Particulars	Quarter ended			Year ended
	30.06.2019	31.03.2019	30.06.2018	31.03.2019
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	144.29	121.86	486.26	805.78
II. Other income	0.01	-	-	-
<b>III.Total revenue (I + II)</b>	<b>144.30</b>	<b>121.86</b>	<b>486.26</b>	<b>805.78</b>
<b>IV. Expenses</b>				
Cost of materials consumed	-	14.40	480.32	614.72
Purchase of Stock-in-Trade	45.05	-	-	-
Changes in inventories of finished goods and stock in trade	0.29	(1.01)	(9.75)	(22.42)
Depreciation and Amortisation	0.06	0.03	-	0.06
Employee benefits expense	60.32	73.00	4.35	109.73
Finance Charges	-	-	0.18	-
Other expenses	27.65	20.80	3.32	59.61
<b>Total expenses</b>	<b>133.37</b>	<b>107.22</b>	<b>478.42</b>	<b>761.70</b>
<b>V. Profit/(Loss) before tax (III - IV)</b>	<b>10.93</b>	<b>14.64</b>	<b>7.84</b>	<b>44.08</b>
<b>VI. Tax expense:</b>				
(1) Current tax	2.62	3.54	-	3.54
(2) Deferred tax	-	-	-	-
<b>VII. Profit/(Loss) for the period (V-VI)</b>	<b>8.31</b>	<b>11.10</b>	<b>7.84</b>	<b>40.54</b>
<b>VIII. Other comprehensive income</b>				
i) Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of a foreign operation	0.07	(0.40)	-	0.10
<b>IX. Total comprehensive income for the year</b>	<b>8.38</b>	<b>10.70</b>	<b>7.84</b>	<b>40.64</b>
Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00
<b>X. Earning per equity share</b>				
(1) Basic	0.10	0.14	0.10	0.51
(2) Diluted	0.10	0.14	0.10	0.51

**Notes**

1) The operations of the Company relate to two segments viz., Manufacturing and trading of Pharmaceutical drugs and Consultancy Services

**Segment Information:**

Particulars	Three Months Ended			Year Ended
	30.06.2019	31.03.2019	30.06.2018	31.03.2019
	Unaudited	Audited	Audited	Audited
<b>Segment Revenue</b>				
a) Manufacturing and trading of Pharmaceutical drugs	47.10	15.51	486.26	629.66
b) Consultancy Services	97.20	106.35	0.00	176.12
<b>Total Sales</b>	<b>144.30</b>	<b>121.86</b>	<b>486.26</b>	<b>805.78</b>
Less: Inter Segment Revenue	-	-	-	-
<b>Total Revenue from Operations</b>	<b>144.30</b>	<b>121.86</b>	<b>486.26</b>	<b>805.78</b>
<b>Segment Result (Profit Before Tax and Interest from each Segment)</b>				
a) Manufacturing and trading of Pharmaceutical drugs	1.30	1.85	7.84	20.65
b) Consultancy Services	9.63	12.79	-	23.43
<b>Total</b>	<b>10.93</b>	<b>14.64</b>	<b>7.84</b>	<b>44.08</b>
Less: Interest	-	-	-	-
<b>Total Profit before tax</b>	<b>10.93</b>	<b>14.64</b>	<b>7.84</b>	<b>44.08</b>
	0.00	0.00	0.00	0.00
<b>Capital employed (Segment assets - segment liabilities)</b>				
<b>Segment assets</b>				
a) Manufacturing and trading of Pharmaceutical drugs	280.70	560.00	860.62	560.00
b) Consultancy Services	85.92	74.20	0.99	74.20
<b>Total Assets</b>	<b>366.62</b>	<b>634.20</b>	<b>861.61</b>	<b>634.20</b>
<b>Segment liabilities</b>				
a) Manufacturing and trading of Pharmaceutical drugs	63.95	334.11	641.75	334.11
b) Consultancy Services	39.51	47.48	0.06	47.48
<b>Total Liabilities</b>	<b>103.46</b>	<b>381.59</b>	<b>641.81</b>	<b>381.59</b>

- 1) The above results for the quarter ended June 2019 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12.08.2019.
- 2) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI circular dated 5 July, 2016.
- 3) The above results include results of wholly owned subsidiaries
  - RA Labs Pte Ltd, Singapore
  - ICP Solutions Private Limited, India
- 4) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

Place: Hyderabad  
Date: 12.08.2019



For and on behalf of the Board

Vasudev Komaraju  
Wholetime Director  
DIN: 07233691

**COMBAT DRUGS LIMITED**

(CIN CL23230TG1986PLC006781)

Regd Office : 4th Floor, Plot No.94, Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019**

S.No	Particulars	Quarter ended			Year ended
		30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	61.06	22.74	485.60	678.11
2	Other Income	0.42	6.10	-	0.88
3	<b>Total income (1+2)</b>	<b>61.48</b>	<b>28.84</b>	<b>485.60</b>	<b>678.98</b>
4	<b>Expenses</b>				
a.	Cost of Materials consumed	-	14.40	480.32	614.72
b.	Purchase of Stock-in-Trade	45.05	-	-	-
c.	Changes in Inventories of Finished Goods, work -in-progress and stock-in -trade	0.29	(1.01)	(9.75)	(22.42)
d.	Employee Benefits Expense	7.88	3.89	4.35	16.68
e.	Depreciation	0.06	0.03	-	0.06
f.	Other Expenses	5.52	3.93	3.27	32.25
	<b>Total Expenses</b>	<b>58.80</b>	<b>21.24</b>	<b>478.19</b>	<b>641.29</b>
5	Profit Before exceptional items and tax (3-4)	2.68	7.60	7.41	37.69
6	Exceptional Items	-	-	-	-
7	<b>Profit Before Tax (5-6)</b>	<b>2.68</b>	<b>7.60</b>	<b>7.41</b>	<b>37.69</b>
8	<b>Tax Expenses</b>				
a.	Current tax	-	-	-	-
b.	Deferred tax	-	0.01	-	0.01
	Total tax	-	0.01	-	0.01
9	Net Profit / (Loss) for the period (7-8)	<b>2.68</b>	<b>7.59</b>	<b>7.41</b>	<b>37.68</b>
10	Other comprehensive income, (net of tax)	-	-	-	-
11	<b>Total comprehensive income for the period (9-10)</b>	<b>2.68</b>	<b>7.59</b>	<b>7.41</b>	<b>37.68</b>
12	Paid-up equity share capital (Face Value of Rs. 10/- each)	800.00	800.00	800.00	800.00
13	Earnings Per Share (EPS) (Basic & Diluted)	0.03	0.09	0.09	0.47

## Notes:

- The above results for the quarter ended 30 June 2019 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12.08.2019. The Statutory Auditors have expressed an unmodified audit opinion.
- The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI circular dated 5 July, 2016.
- The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Vasudev Komaraju  
Wholetime Director  
DIN: 07233691

Place: Hyderabad  
Date: 12.08.2019

**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Review Report to  
The Board of Directors  
Combat Drugs Limited**


1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Combat Drugs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. The Statement includes the results of the following entities:  
ICP Solutions Private Limited, India  
RA Labs Pte Ltd, Singapore
5. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of 1 subsidiary ie RA Labs Pte Ltd, Singapore whose interim financial results/information reflects total revenue of Rs. Nil lakh, total net loss after tax of Rs. 0.18 lakh and total comprehensive Income of Rs. Nil lakh for the quarter ended 30th June, 2019, which are certified by the management. According to the information and explanations given to us by the Management, these interim financial results and other financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For M.Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.0001255)

  
Y.Lakshmi Nagarathnam  
Partner

M.No: 212926

UDIN: 19212926AAAAAY4900



Place: Hyderabad

Date: 12<sup>th</sup> August, 2019

**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results  
of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure  
Requirements) Regulations, 2015**

**Review Report to  
The Board of Directors  
Combat Drugs Limited**

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Combat Drugs Limited for the quarter ended 30<sup>th</sup> June, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.0001255)

*Y. Lakshmi Nagaratnam*

Y.Lakshmi Nagaratnam  
Partner

Membership Number: 212926

UDIN: 19212926AAAAA29790

Place: Hyderabad

Date: 12<sup>th</sup> August, 2019

